ETF Series Solutions Trust Range Cancer Therapeutics ETF
CNCR
CNCR was delisted on the 27th of May, 2025.
16 hedge funds and large institutions have $2.29M invested in ETF Series Solutions Trust Range Cancer Therapeutics ETF in 2024 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 2 closing their positions.
150% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 2
34% more capital invested
Capital invested by funds: $1.7M → $2.29M (+$585K)
23% more funds holding
Funds holding: 13 → 16 (+3)
1.09% more ownership
Funds ownership: 12.28% → 13.37% (+1.1%)
0% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$381K |
| 2 |
Jane Street
New York
|
+$177K |
| 3 |
Focus Partners Wealth
Boston,
Massachusetts
|
+$177K |
| 4 |
Morgan Stanley
New York
|
+$90.9K |
| 5 |
RIA
Realta Investment Advisors
Wilmington,
Delaware
|
+$8.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$539K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$21.2K |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$15K |
| 4 |
BBPWM
Blue Bell Private Wealth Management
Blue Bell,
Pennsylvania
|
-$10.7K |
| 5 |
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
|
-$8.05K |
CNCR Hedge Fund Activity: Q1 2024 in Review
16 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) for Q1 2024, worth a combined $2.29M — up 34% from $1.7M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new CNCR positions and 2 closed out — a net gain of 3 holders — while 3 added to existing stakes and 3 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $381K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $539K sold.
- 16 institutional investors held ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) as of Q1 2024, up from 13 in Q4 2023.
- Funds reported $2.29M of ETF Series Solutions Trust Range Cancer Therapeutics ETF stock for Q1 2024, up 34% quarter-over-quarter.
- 5 funds opened new ETF Series Solutions Trust Range Cancer Therapeutics ETF positions in Q1 2024 and 2 closed out, a net change of +3 holders.
- The largest ETF Series Solutions Trust Range Cancer Therapeutics ETF buyer in Q1 2024 was Citadel Advisors, an estimated $381K added.
- The largest ETF Series Solutions Trust Range Cancer Therapeutics ETF seller in Q1 2024 was Susquehanna International Group, an estimated $539K sold.
Based on aggregated 13F filings for Q1 2024.